港股異動 | 信達生物漲5%股價創逾半年新高 2型糖尿病臨牀試驗完成患者給藥
格隆匯1月11日丨信達生物(1801.HK)漲5.59%,報39.7港元,總市值609億港元,股價創2022年7月6日新高。信達生物宣佈,胰高血糖素樣肽-1受體(glucagon-like peptide-1 receptor, GLP-1R)/胰高血糖素受體(glucagon receptor, GCGR)雙重激動劑mazdutide(研發代號:IBI362)在中國2型糖尿病受試者中的一項多中心、隨機、度拉糖肽對照的III期臨牀研究(DREAMS-2)完成首例受試者給藥。此外,瑞銀髮研報稱,在醫藥板塊中該行首選信達生物等。該行對國內醫療保健板塊看法樂觀,因行業政策可預測度更高、企業基本面改善,以及板塊估值處於歷史谷底。同時預計今年創新及復甦將成兩大主題,並指在生物科技、醫療科技、藥店、醫療服務、CRO及疫苗板塊藴藏機遇。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.